Chad May is a highly experienced executive in the biotechnology and pharmaceutical industries, currently serving as Chief Scientific Officer at Orum Therapeutics since December 2025. Prior to this role, Chad was Head of Serotiny within Johnson & Johnson Innovative Medicine, where responsibilities included co-leading the integration of Serotiny post-acquisition. Chad previously held the position of Chief Scientific Officer at Serotiny, overseeing preclinical development of a novel gene and cell therapy platform. As Senior Vice President of Research and Development at Maverick Therapeutics, Chad co-founded the company and successfully advanced conditionally active bispecific T cell engagers into Phase 1 trials. Earlier career roles include Senior Director of Targeted Immunotherapy at Pfizer and Senior Scientist at ImClone Systems, with foundational experience gained as a Post Doctoral Fellow at Memorial Sloan Kettering Cancer Center and a Research Associate at the University of Minnesota. Chad holds a PhD in Immunology from Joan & Sanford I. Weill Medical College of Cornell University and a B.S. in Genetics and Cell Biology from the University of Minnesota.
This person is not in any teams
This person is not in any offices